Emergent BioSolutions announced that its COVID-19 Human Immune Globulin (COVID-HIG) product candidate will be evaluated in an NIH-sponsored phase 3 clinical trial of hyperimmune intravenous immunoglobulins to treat COVID-19
GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therapy COVID-HIG as a potential treatment for hospitalized patients with coronavirus disease (COVID-19). The INSIGHT-013 clinical study called “Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC),” is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study will evaluate the safety, tolerability, and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies to SARS-CoV-2, the virus that causes COVID-19. The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of four hyperimmune globulin products, which includes Emergent’s COVID-HIG, with a background therapy of remdesivir in all groups.
Neumann University Sisters Offer Prayers From the Porch
Coronavirus has caused most of the Sisters of St. Francis at Neumann University to maintain a healthy social distance from the students there.
Despite this hurdle, Sr. Marguerite O’Beirne, OSF, Neumann’s vice president for mission and ministry, and Sr. Linda DeCero, OSF, director of pastoral ministry, aren’t letting the virus interfere with their roles on campus.
Thank you to our member who continue to support the Chamber through their membership, you make our mission possible!
Renewing members in September:
• Timothy Hillert, BenXchange
• James Burns
• Bill Watkinson, Watkinson Capital
• James O’Connor, St. Patrick’s College, Maynooth
• Richard Meehan, Meehan Wealth Advisors, LLC
Brian Tierney is happy to announce Tierney Business Networks will continue where Streamline Payroll left off.
The attached brochure is a golf outing supporting Family Services of Buck County. This organizations has supported families in need in our area for years. Brian is on the board for the golf committee helping to promote and support this event. He will be there on October 5th continuing to network, promoting business and charity event similar to this.
Irish drug that could cure Parkinson’s Disease sold for $446 million
Dr. Jeremy Skillington, Vice President of Business Development for Inflazome, travelled to Philadelphia to participate in our Life Sciences Forum this January. In one of the largest deals in Irish biotech history, Inflazome, based out of Trinity, has been sold to Roche.
The Dublin-based drug sells opening treatment of Alzheimer’s, Parkinson’s, and cardiovascular disease to the market.
An Irish company that develops treatments for inflammatory diseases, a collaboration between Trinity College Dublin and the University of Queensland, has been sold for an up-front payment of $446m (€380m) from Roche, plus additional payments based on the achievement of certain milestones.